Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIACADADMAAGIOALMSALMUALTSAPGEAUPHAVAVBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTRIGCTGOOGGPCRHALOHIMSHOODHWMIRENIVVDKALAKALVLENZLEVILITELRMRLULULUNRMDGLMESOMOHMTCHMUMVSTNBISNKENRIXNVAXOKUROLMAONCOSCRPHATPLRXPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHAUNHVEONVORWVEXFORZLAB
BioCryst Pharmaceuticals (BCRX) has achieved a critical inflection point, transitioning to profitability driven by its oral HAE drug ORLADEYO® (156.8MQ22025revenue,+45249M debt, projecting 700M cash by 2027. The companyt argets 1B peak sales for ORLADEYO, supported by pediatric expansion (PDUFA Dec 2025) and strong U.S. growth. Pipeline catalysts include Phase 1 data for BCX17725 (Netherton Syndrome) and Avoralstat (Diabetic Macular Edema) by end-2025. Trading at 3.3x P/S with 95% analyst "Buy" ratings, BCRX presents compelling upside as a debt-free rare disease platform leveraging its commercial engine for consolidation.

BioCryst Pharmaceuticals (BCRX): An In-Depth Investment Analysis at the Inflection Point of Profitability

2025-08-04Change from report: +9.5%1M: -5.3%3M: -22.6%

BioCryst Pharmaceuticals (BCRX) has achieved a critical inflection point, transitioning to profitability driven by its oral HAE drug ORLADEYO® (156.8MQ22025revenue,+45249M debt, projecting 700M cash by 2027. The companyt argets 1B peak sales for ORLADEYO, supported by pediatric expansion (PDUFA Dec 2025) and strong U.S. growth. Pipeline catalysts include Phase 1 data for BCX17725 (Netherton Syndrome) and Avoralstat (Diabetic Macular Edema) by end-2025. Trading at 3.3x P/S with 95% analyst "Buy" ratings, BCRX presents compelling upside as a debt-free rare disease platform leveraging its commercial engine for consolidation.